Actions

Luke: Difference between revisions

From MalariaETC

No edit summary
No edit summary
 
(3 intermediate revisions by the same user not shown)
Line 1: Line 1:
----
This is where you put your text
then add stuff
----


<gallery mode="traditional" widths=160px heights=160px>
<h2>PML::RARA – Low Risk APL</h2>
File:Possible primitive cells PR.jpg|center|<span style="font-size:4000%"></gallery>
<table style="border-collapse: collapse; width: 100%; margin-bottom: 2em;">
  <tr>
    <th style="border: 1px solid #999; padding: 0.5em; text-align: left; vertical-align: top; background-color: #f2f2f2;">Gene</th>
    <th style="border: 1px solid #999; padding: 0.5em; text-align: left; vertical-align: top; background-color: #f2f2f2;">Timepoints – on treatment</th>
    <th style="border: 1px solid #999; padding: 0.5em; text-align: left; vertical-align: top; background-color: #f2f2f2;">Duration</th>
    <th style="border: 1px solid #999; padding: 0.5em; text-align: left; vertical-align: top; background-color: #f2f2f2;">Follow-up post therapy</th>
    <th style="border: 1px solid #999; padding: 0.5em; text-align: left; vertical-align: top; background-color: #f2f2f2;">Notes</th>
  </tr>
  <tr>
    <td style="border: 1px solid #999; padding: 0.5em; vertical-align: top;">PML::RARA</td>
    <td style="border: 1px solid #999; padding: 0.5em; vertical-align: top;">Bone marrow MRD – post each cycle of treatment</td>
    <td style="border: 1px solid #999; padding: 0.5em; vertical-align: top;">Stop performing MRD once CRMRD</td>
    <td style="border: 1px solid #999; padding: 0.5em; vertical-align: top;"></td>
    <td style="border: 1px solid #999; padding: 0.5em; vertical-align: top;">Recommended by both ELN and Dillon et al</td>
  </tr>
</table>
 
<h2>PML::RARA – High Risk APL</h2>
<table style="border-collapse: collapse; width: 100%; margin-bottom: 2em;">
  <tr>
    <th style="border: 1px solid #999; padding: 0.5em; text-align: left; vertical-align: top; background-color: #f2f2f2;">Gene</th>
    <th style="border: 1px solid #999; padding: 0.5em; text-align: left; vertical-align: top; background-color: #f2f2f2;">Timepoints – on treatment</th>
    <th style="border: 1px solid #999; padding: 0.5em; text-align: left; vertical-align: top; background-color: #f2f2f2;">Duration</th>
    <th style="border: 1px solid #999; padding: 0.5em; text-align: left; vertical-align: top; background-color: #f2f2f2;">Follow-up post therapy</th>
    <th style="border: 1px solid #999; padding: 0.5em; text-align: left; vertical-align: top; background-color: #f2f2f2;">Notes</th>
  </tr>
  <tr>
    <td style="border: 1px solid #999; padding: 0.5em; vertical-align: top;">PML::RARA</td>
    <td style="border: 1px solid #999; padding: 0.5em; vertical-align: top;">Bone marrow MRD – post each cycle of treatment</td>
    <td style="border: 1px solid #999; padding: 0.5em; vertical-align: top;"></td>
    <td style="border: 1px solid #999; padding: 0.5em; vertical-align: top;">BM MRD every 3 months for 2–3 years</td>
    <td style="border: 1px solid #999; padding: 0.5em; vertical-align: top;">
      Recommended by both ELN and Dillon et al<br>
      ELN recommend 2 years
    </td>
  </tr>
</table>
 
<h2>NPM1</h2>
<table style="border-collapse: collapse; width: 100%; margin-bottom: 2em;">
  <tr>
    <th style="border: 1px solid #999; padding: 0.5em; text-align: left; vertical-align: top; background-color: #f2f2f2;">Gene</th>
    <th style="border: 1px solid #999; padding: 0.5em; text-align: left; vertical-align: top; background-color: #f2f2f2;">Timepoints – on treatment</th>
    <th style="border: 1px solid #999; padding: 0.5em; text-align: left; vertical-align: top; background-color: #f2f2f2;">Additional tests</th>
    <th style="border: 1px solid #999; padding: 0.5em; text-align: left; vertical-align: top; background-color: #f2f2f2;">Follow-up post therapy</th>
    <th style="border: 1px solid #999; padding: 0.5em; text-align: left; vertical-align: top; background-color: #f2f2f2;">Notes</th>
  </tr>
  <tr>
    <td style="border: 1px solid #999; padding: 0.5em; vertical-align: top;">NPM1</td>
    <td style="border: 1px solid #999; padding: 0.5em; vertical-align: top;">Bone marrow MRD – post each cycle of treatment</td>
    <td style="border: 1px solid #999; padding: 0.5em; vertical-align: top;">PB MRD sample post cycle 2</td>
    <td style="border: 1px solid #999; padding: 0.5em; vertical-align: top;">
      BM 3 monthly for 2 years<br>
      PB 2 monthly for 2 years
    </td>
    <td style="border: 1px solid #999; padding: 0.5em; vertical-align: top;">
      Post #2 PB sample based on AML 17 and Dillon et al<br>
      *Recommendations based on Dillon et al.<br>
      ELN recommends PB monitoring 4–6 weekly
    </td>
  </tr>
</table>

Latest revision as of 10:23, 31 July 2025

PML::RARA – Low Risk APL

Gene Timepoints – on treatment Duration Follow-up post therapy Notes
PML::RARA Bone marrow MRD – post each cycle of treatment Stop performing MRD once CRMRD Recommended by both ELN and Dillon et al

PML::RARA – High Risk APL

Gene Timepoints – on treatment Duration Follow-up post therapy Notes
PML::RARA Bone marrow MRD – post each cycle of treatment BM MRD every 3 months for 2–3 years 
     Recommended by both ELN and Dillon et al

     ELN recommend 2 years

NPM1

Gene Timepoints – on treatment Additional tests Follow-up post therapy Notes
NPM1 Bone marrow MRD – post each cycle of treatment PB MRD sample post cycle 2 
     BM 3 monthly for 2 years

     PB 2 monthly for 2 years

     Post #2 PB sample based on AML 17 and Dillon et al

     *Recommendations based on Dillon et al.

     ELN recommends PB monitoring 4–6 weekly
Retrieved from "https://haematologyetc.org/index.php?title=Luke&oldid=3613"